Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer von Chi, Kim N, Agarwal, Neeraj, Bjartell, Anders, Chung, Byung Ha, Pereira de Santana Gomes, Andrea J, Given, Robert, Juárez Soto, Álvaro, Merseburger, Axel S, Özgüroğlu, Mustafa, Uemura, Hirotsugu, Ye, Dingwei, Deprince, Kris, Naini, Vahid, Li, Jinhui, Cheng, Shinta, Yu, Margaret K, Zhang, Ke, Larsen, Julie S, McCarthy, Sharon, Chowdhury, Simon

Volltext

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer von Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

Volltext

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer von Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A, Özgüroğlu, Mustafa

Volltext

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer von Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C, Todd, Mary B, Chi, Kim N

Volltext

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer von Hussain, Maha, Mateo, Joaquin, Fizazi, Karim, Saad, Fred, Shore, Neal, Sandhu, Shahneen, Chi, Kim N, Sartor, Oliver, Agarwal, Neeraj, Olmos, David, Thiery-Vuillemin, Antoine, Twardowski, Przemyslaw, Roubaud, Guilhem, Özgüroğlu, Mustafa, Kang, Jinyu, Burgents, Joseph, Gresty, Christopher, Corcoran, Claire, Adelman, Carrie A, de Bono, Johann

Volltext

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC von Herbst, Roy S, Giaccone, Giuseppe, de Marinis, Filippo, Reinmuth, Niels, Vergnenegre, Alain, Barrios, Carlos H, Morise, Masahiro, Felip, Enriqueta, Andric, Zoran, Geater, Sarayut, Özgüroğlu, Mustafa, Zou, Wei, Sandler, Alan, Enquist, Ida, Komatsubara, Kimberly, Deng, Yu, Kuriki, Hiroshi, Wen, Xiaohui, McCleland, Mark, Mocci, Simonetta, Jassem, Jacek, Spigel, David R

Volltext

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 von Van Cutsem, Eric, Amonkar, Mayur, Fuchs, Charles S., Alsina, Maria, Özgüroğlu, Mustafa, Bang, Yung-Jue, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, Benson, Al B., Sun, Weijing, Wainberg, Zev A., Norquist, Josephine M., Chen, Xinqun, Shih, Chie-Schin, Shitara, Kohei

Volltext

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 1... von Moehler, Markus, Dvorkin, Mikhail, Boku, Narikazu, Ozguroglu, Mustafa, Ryu, Min-Hee, Muntean, Alina S., Lonardi, Sara, Nechaeva, Marina, Bragagnoli, Arinilda C., Coskun, Hasan S., Cubillo Gracian, Antonio, Takano, Toshimi, Wong, Rachel, Safran, Howard, Vaccaro, Gina M., Wainberg, Zev A., Silver, Matthew R., Xiong, Huiling, Hong, Janet, Taieb, Julien, Bang, Yung-Jue

Volltext

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 tria... von Fuchs, Charles S., Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesinski, Tomasz, Caglevic, Christian, Chung, Hyun C., Muro, Kei, Van Cutsem, Eric, Elme, Anneli, Thuss-Patience, Peter, Chau, Ian, Ohtsu, Atsushi, Bhagia, Pooja, Wang, Anran, Shih, Chie-Schin, Shitara, Kohei

Volltext

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlle... von Sezer, Ahmet, Kilickap, Saadettin, Gümüş, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M, Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip, Sriuranpong, Virote, Rizvi, Naiyer, Gao, Bo, Li, Siyu, Lee, Sue, McGuire, Kristina, Chen, Chieh-I, Makharadze, Tamta, Paydas, Semra, Nechaeva, Marina, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Gullo, Giuseppe, Lowy, Israel, Rietschel, Petra

Volltext

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report von Chen, Yuanbin, Paz-Ares, Luis, Reinmuth, Niels, Garassino, Marina Chiara, Statsenko, Galina, Hochmair, Maximilian J., Özgüroğlu, Mustafa, Verderame, Francesco, Havel, Libor, Losonczy, György, Conev, Nikolay V., Hotta, Katsuyuki, Ji, Jun Ho, Spencer, Stuart, Dalvi, Tapashi, Jiang, Haiyi, Goldman, Jonathan W.

Volltext

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study von Barlesi, Fabrice, Vansteenkiste, Johan, Spigel, David, Ishii, Hidenobu, Garassino, Marina, de Marinis, Filippo, Özgüroğlu, Mustafa, Szczesna, Aleksandra, Polychronis, Andreas, Uslu, Ruchan, Krzakowski, Maciej, Lee, Jong-Seok, Calabrò, Luana, Arén Frontera, Osvaldo, Ellers-Lenz, Barbara, Bajars, Marcis, Ruisi, Mary, Park, Keunchil

Volltext

Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 von Van Cutsem, Eric, Amonkar, Mayur, Fuchs, Charles S., Alsina, Maria, Özgüroğlu, Mustafa, Bang, Yung-Jue, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, Benson, Al B., Sun, Weijing, Wainberg, Zev A., Norquist, Josephine M., Chen, Xinqun, Shih, Chie-Schin, Shitara, Kohei

Volltext

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC von Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, Antonia, Scott J.

Volltext

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial von Faivre-Finn, Corinne, Vicente, David, Kurata, Takayasu, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F., Spigel, David R., Garassino, Marina C., Reck, Martin, Senan, Suresh, Naidoo, Jarushka, Rimner, Andreas, Wu, Yi-Long, Gray, Jhanelle E., Özgüroğlu, Mustafa, Lee, Ki H., Cho, Byoung C., Kato, Terufumi, de Wit, Maike, Newton, Michael, Wang, Lu, Thiyagarajah, Piruntha, Antonia, Scott J.

Volltext

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial von Galsky, Matthew D, Arija, José Ángel Arranz, Bamias, Aristotelis, Davis, Ian D, De Santis, Maria, Kikuchi, Eiji, Garcia-del-Muro, Xavier, De Giorgi, Ugo, Mencinger, Marina, Izumi, Kouji, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Kalebasty, Arash Rezazadeh, Park, Se Hoon, Alekseev, Boris, Schutz, Fabio A, Li, Jian-Ri, Ye, Dingwei, Vogelzang, Nicholas J, Bernhard, Sandrine, Tayama, Darren, Mariathasan, Sanjeev, Mecke, Almut, Thåström, AnnChristine, Grande, Enrique

Volltext

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer von Kato, Ken, Shah, Manish A, Enzinger, Peter, Bennouna, Jaafar, Shen, Lin, Adenis, Antoine, Sun, Jong-Mu, Cho, Byoung Chul, Özgüro lu, Mustafa, Kojima, Takashi, Kostorov, Vladimir, Hierro, Cinta, Zhu, Ying, McLean, Lee Anne, Shah, Sukrut, Doi, Toshihiko

Volltext

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study von Chi, Kim N., Chowdhury, Simon, Bjartell, Anders, Byung Ha Chung, Gomes, Andrea J. Pereira de Santana, Given, Robert, Juarez, Alvaro, Merseburger, Axel S., Ozguroglu, Mustafa, Uemura, Hirotsugu, Ye, Dingwei, Brookman-May, Sabine, Mundle, Suneel D., McCarthy, Sharon A., Larsen, Julie S., Sun, Weili, Bevans, Katherine B., Zhang, Ke, Bandyopadhyay, Nibedita, Agarwal, Neeraj

Volltext

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study von Hui, Rina, Özgüroğlu, Mustafa, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki Hyeong, de Wit, Maike, Cho, Byoung Chul, Gray, Jhanelle E, Rydén, Anna, Viviers, Louis, Poole, Lynne, Zhang, Yiduo, Dennis, Phillip A, Antonia, Scott J

Volltext

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with A... von Matsubara, Nobuaki, Chi, Kim N., Özgüroğlu, Mustafa, Rodriguez-Antolin, Alfredo, Feyerabend, Susan, Fein, Luis, Alekseev, Boris Y., Sulur, Giri, Protheroe, Andrew, Li, Susan, Mundle, Suneel, De Porre, Peter, Tran, Namphuong, Fizazi, Karim

Volltext